Evaluation of cilofungin (LY121019) for treatment of experimental Candida albicans endocarditis in rabbits.
AUTOR(ES)
Padula, A
RESUMO
The efficacy of cilofungin (LY121019) for aortic valve endocarditis caused by Candida albicans in rabbits was studied. Vegetation titers were similar for cilofungin-treated and untreated rabbits. No rabbit survived beyond 5 days in either group. All rabbits given amphotericin B survived, and titers were reduced. Cilofungin was ineffective in this model.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=172764Documentos Relacionados
- Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits.
- Cilofungin (LY121019) inhibits Candida albicans (1-3)-beta-D-glucan synthase activity.
- Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice.
- Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits.
- Cilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis.
